Combination drug treatment in obese diabetic patients  

作　　者：Theodosios D Filippatos Moses S Elisaf 

机构地区：[1]Department of Internal Medicine,University of Ioannina

出　　处：《World Journal of Diabetes》2010年第1期8-11,共4页世界糖尿病杂志（英文版）（电子版）

摘　　要：Drug combinations that include antiobesity drugs(such as orlistat and sibutramine) and target cardiovascular disease(CVD) risk factors may be a good approach to patients with type 2 diabetes and/or metabolic syndrome(MetS).Our group has investigated the orlistat-fenofibrate combination treatment in obese patients with MetS and the orlistat-ezetimibe and the sibutramine-antihypertensive combination treatment in obese patients with hyperlipidaemia with promising results in CVD risk factor reduction.In these studies,the combination treatment significantly improved the lipid and lipoprotein profile,the carbohydrate metabolism parameters and many other variables playing a role in the atherosclerotic process.Small studies give pro m ising results but double-blind,randomized trials examining the effects of such multif actorial treatment in hard CVD endpoints in diabet ic or MetS patients are missing.Drug combinations that include antiobesity drugs (such as orlistat and sibutramine) and target cardiovascular disease (CVD) risk factors may be a good approach to patients with type 2 diabetes and/or metabolic syndrome (MetS). Our group has investigated the orlistat-fenofibrate combination treatment in obese patients with MetS and the orlistat-ezetimibe and the sibutramine-antihypertensive combination treatment in obese patients with hyperlipidaemia with promising results in CVD risk factor reduction. In these studies, the combination treatment significantly improved the lipid and lipoprotein profile, the carbohydrate metabolism parameters and many other variables playing a role in the atherosclerotic process. Small studies give promising results but double-blind, randomized trials examining the effects of such multifactorial treatment in hard CVD endpoints in diabetic or MetS patients are missing.

关 键 词：Diabetes METABOLIC syndrome ORLISTAT SIBUTRAMINE FENOFIBRATE EZETIMIBE Weight loss 

分 类 号：R587.1[医药卫生—内分泌]